DKSH N/ CH0126673539 /
2024-05-10 5:31:10 PM | Chg. 0.00 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
62.20CHF | 0.00% | 62,125 Turnover: 3.87 mill. |
62.00Bid Size: 80 | 63.00Ask Size: 71 | 4.05 bill.CHF | 3.62% | 22.21 |
GlobeNewswire
04-30
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire
04-24
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimil...
GlobeNewswire
04-19
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...
GlobeNewswire
04-16
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
GlobeNewswire
03-05
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
GlobeNewswire
02-26
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purc...
GlobeNewswire
02-24
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interc...
GlobeNewswire
02-15
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
GlobeNewswire
01-29
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Bios...
GlobeNewswire
01-19
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
GlobeNewswire
01-10
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
GlobeNewswire
01-03
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT...
GlobeNewswire
2023-11-29
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Bios...
GlobeNewswire
2023-11-28
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
GlobeNewswire
2023-11-21
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Hos...
GlobeNewswire
2023-11-14
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First...
GlobeNewswire
2023-11-10
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelar...
GlobeNewswire
2023-10-12
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04